LLY rides its success against obesity and diabetes LONG
LLY shown on a daily chart has doubled in the past year with the introduction of new FDA
approved drugs into the market. It has but out a series of favorable earnings reports with
optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume
pumps and just keeps grinding higher. This is because it is in the shadows of big technology
stocks. Revenues consistently beat analysts' forecasts quarter after quarter.
Institutions add small lots trying to preserve the price for future buys without any
run-ups. I have done the same thing and I will continue to do so. While day trading
biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are
parked for growth and compounding.
approved drugs into the market. It has but out a series of favorable earnings reports with
optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume
pumps and just keeps grinding higher. This is because it is in the shadows of big technology
stocks. Revenues consistently beat analysts' forecasts quarter after quarter.
Institutions add small lots trying to preserve the price for future buys without any
run-ups. I have done the same thing and I will continue to do so. While day trading
biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are
parked for growth and compounding.
Comentarios:
Zoom-in shows buys at HLs and a sell at a HH since earnings-
